XML 27 R14.htm IDEA: XBRL DOCUMENT
v3.19.1

Stockholders' Equity | 9 Months Ended
--- | ---
Mar. 31, 2019
Stockholders' Equity |
Stockholders' Equity | 7. Stockholders’ Equity Stock-based Compensation As of March 31, 2019, we maintained the Amended and Restated 2012 Incentive Award Plan (the “2012 Plan”) and the Amended and Restated 2006 Equity Participation Plan (“2006 Plan”) as stock-based employee compensation plans. No further grants may be made under the 2006 Plan. In addition, pursuant to the acquisition of American Science and Engineering, Inc. (“AS&E”), we assumed two stock-based employee compensation plans: the AS&E 2005 Equity and Incentive Plan and the AS&E 2014 Equity and Incentive Plan (collectively the " AS&E Plans”). No new equity grants will be made under the AS&E Plans. The 2012 Plan, the 2006 Plan, and the AS&E Plans are collectively referred to as the “OSI Plans”. We recorded stock-based compensation expense in the condensed consolidated statements of operations as follows (in thousands):
|  | Three Months Ended March 31, |  | Nine Months Ended March 31,
|  | 2018 |  | 2019 |  | 2018 |  | 2019
Cost of goods sold |  | $ | 251 |  | $ | 182 |  | $ | 739 |  | $ | 539
Selling, general and administrative |  |  | 5,614 |  |  | 5,543 |  |  | 16,574 |  |  | 18,487
Research and development |  |  | 149 |  |  | 163 |  |  | 441 |  |  | 488
Stock-based compensation expense |  | $ | 6,014 |  | $ | 5,888 |  | $ | 17,754 |  | $ | 19,514
As of March 31, 2019, total unrecognized compensation cost related to stock-based compensation grants under the OSI Plans were estimated at $0.6 million for stock options and $19.4 million for RSUs. We expect to recognize these costs over a weighted average period of 2.0 years with respect to the stock options and 1.9 years for grants of RSUs. The following summarizes stock option activity during the nine months ended March 31, 2019:
|  |  |  | Weighted Average |  | Weighted-Average |  | Aggregate
|  | Number of |  | Exercise |  | Remaining Contractual |  | Intrinsic Value
|  | Options |  | Price |  | Term |  | (in thousands)
Outstanding at June 30, 2018 |  | 677,525 |  | $ | 32.80 |  |  |  |  |
Granted |  | 18,135 |  | $ | 72.39 |  |  |  |  |
Exercised |  | (108,008) |  | $ | 22.82 |  |  |  |  |
Expired or forfeited |  | (9,618) |  | $ | 70.28 |  |  |  |  |
Outstanding at March 31, 2019 |  | 578,034 |  | $ | 35.29 |  | 2.6 years |  | $ | 30,247
Exercisable at March 31, 2019 |  | 540,646 |  | $ | 32.37 |  | 2.1 years |  | $ | 29,865
The following summarizes RSU award activity during the nine months ended March 31, 2019:
|  |  |  | Weighted-
|  |  |  | Average
|  | Shares |  | Fair Value
Nonvested at June 30, 2018 |  | 526,377 |  | $ | 71.56
Granted |  | 362,025 |  |  | 73.80
Vested |  | (357,924) |  |  | 71.01
Forfeited |  | (13,669) |  |  | 73.74
Nonvested at March 31, 2019 |  | 516,809 |  | $ | 73.45
As of March 31, 2019, there were approximately 1.6 million shares available for grant under the 2012 Plan. Under the terms of the 2012 Plan, RSUs granted from the pool of shares available for grant reduce the pool by 1.87 shares for each award granted. RSUs forfeited and returned to the pool of shares available for grant increase the pool by 1.87 shares for each award forfeited. We granted 117,346 and 97,514 performance-based RSUs during the nine months ended March 31, 2018 and 2019, respectively. These performance based RSU awards are contingent on the achievement of certain performance metrics. The payout related to these awards can range from zero to 280% of the original number of shares or units awarded. Share Repurchase Program In March 2018, our Board of Directors authorized a share repurchase program of up to 1,000,000 shares. This program does not expire unless our Board of Directors acts to terminate the program. The timing and actual number of shares purchased depend on a variety of factors, including stock price, general business and market conditions and other investment opportunities and may be purchased through the open market. Upon repurchase, the shares are restored to the status of authorized but unissued, and we record them as a reduction in the number of shares of common stock issued and outstanding in our consolidated financial statements. We did not repurchase any shares during the three months ended March 31, 2019. During the nine months ended March 31, 2019, we repurchased 288,316 shares of our common stock, and as of March 31, 2019, there were 562,707 shares available to repurchase under the program.

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration